TG Therapeutics Q1 BRIUMVI US rev $194.8M; raises FY guidance to $885-900M

TG THERAPEUTICS, INC.

2026-Q1 EPS reported $0.12 revenue$204,918,000

Q1 2026 total global revenue approx $205M; BRIUMVI U.S. net product revenue $194.8M (+63% YoY).
Net income $19.8M vs $5.1M YoY; product revenue $201.3M vs $119.7M YoY.
Raises FY 2026 BRIUMVI U.S. net product revenue target to $885-900M; Q2 target ~$220M.
Cash $572.8M at March 31, 2026; repurchased $100M of stock in Q1 at avg $29.28/share.
Pipeline: ENHANCE Phase 3 data mid-2026; subcutaneous BRIUMVI data year-end 2026/Q1 2027; azer-cel data H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TG THERAPEUTICS, INC. updated its the three months ended March 31, 2026 guidance (raised).

Period: the three months ended March 31, 2026
Guidance: raised
Result: reported results

Exact text from the filing

On May 6, 2026, the Company issued a press release announcing results of operations for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-015013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.